Verona Pharma plc (VRNA)
$106.91+0.11%Close
BUYBULL · day 63
Key stats
- Market cap
- $9.1B
- Beta
- 0.05
- P/E (TTM)
- -63.64
- 1W
- +0.28%
- 1M
- +0.56%
- vs SPY 1W
- -0.88%
- vs SPY 1M
- -2.43%
Industry peers
FMP comparable companies · ranked by market cap
- BDXSELLBecton, Dickinson and Company$50.6BBULLQ 21$183.75+0.55%
- SGENSeagen Inc.$43.2B$228.74
- ONCBUYBeOne Medicines AG$37.9BBEARQ 30$354.47+1.24%
- KRTXKaruna Therapeutics, Inc.$12.6B$329.83
- RXDXPrometheus Biosciences, Inc.$9.6B$199.92
- IMGNImmunoGen, Inc.$8.7B$31.23
- BPMCBlueprint Medicines Corporation$8.4B$129.46
- RETAReata Pharmaceuticals, Inc.$6.6B$172.36
- ALPNAlpine Immune Sciences, Inc.$4.5B$64.97
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on VRNA?
- LOPJLB’s latest quantitative signal on Verona Pharma plc (VRNA) is BUY in a BULL regime. Signals are updated daily.
- What market regime is VRNA in?
- Verona Pharma plc (VRNA) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Verona Pharma plc (VRNA) do?
- Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes…